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Abstract
Background: The role of combined prothrombotic genotypes in cancer-related ve-
nous thromboembolism (VTE) is scarcely studied. We aimed to investigate the impact 
of a 5-single nucleotide polymorphism (SNP) score on the risk of VTE in patients with 
and without cancer using a population-based case-cohort.
Methods: Cases with a first VTE (n = 1493) and a subcohort (n = 13 072) were de-
rived from the Tromsø Study (1994-2012) and the Nord-Trøndelag Health Study 
(1995-2008). Five SNPs previously reported as a risk score were genotyped: ABO 
(rs8176719), F5 (rs6025), F2 (rs1799963), FGG (rs2066865), and F11 (rs2036914). 
Hazard ratios (HRs) for VTE were estimated according to cancer status and the num-
ber of risk alleles in the 5-SNP score (0-1, 2-3, and ≥4 alleles).
Results: During a median follow-up of 12.3 years, 1496 individuals were diagnosed 
with cancer, of whom 232 experienced VTE. The VTE risk increased with the number 
of risk alleles in the 5-SNP score among subjects without and with cancer. In cancer-
free subjects, the HR was 2.17 (95% confidence interval [CI] 1.79-2.62) for ≥4 versus 
0-1 risk alleles. In cancer patients, the corresponding HR was 1.93 (95% CI 1.28-2.91). 
The combination of cancer and ≥4 risk alleles yielded a 17-fold (HR 17.1, 95% CI 12.5-
23.4) higher risk of VTE compared with cancer-free subjects with 0-1 risk alleles.
Conclusion: The risk of VTE increases with the number of prothrombotic risk alleles 
in subjects with and without cancer, and the combination of prothrombotic risk al-
leles and cancer leads to a highly elevated risk of VTE.
K E Y W O R D S
5-SNP score, cancer, deep vein thrombosis, prothrombotic genotypes, pulmonary embolism, 
risk, venous thromboembolism
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1  | INTRODUC TION
Venous thromboembolism (VTE), a collective term for deep vein 
thrombosis (DVT) and pulmonary embolism (PE), is a severe and fre-
quent complication of malignancy, of which the incidence is increas-
ing.1,2 Cancer is associated with a four- to seven-fold increased risk of 
VTE,3-5 and approximately 15% of cancer patients will develop a VTE 
during the course of malignancy.6 Cancer patients who develop VTE 
have shortened life expectancy compared with cancer patients with-
out VTE.7,8 The clinical consequences of VTE, such as post-thrombotic 
syndrome, VTE recurrence, and treatment-related bleeding, occur 
more often in cancer patients than in cancer-free subjects.7,9 Current 
guidelines do not recommend routine thromboprophylaxis to all am-
bulatory cancer patients due to the uncertain benefit-to-harm ratio, 
which emphasizes the importance of identifying high-risk subjects.10-12
Simulation studies have shown that mapping genetic profiles 
may be useful to detect subjects at high and low risk of disease.13,14 
Genetic profiling may therefore help to identify subjects in need of 
VTE prophylaxis in high-risk situations, such as cancer, surgery, or 
prolonged immobilization. Several single nucleotide polymorphisms 
(SNPs) are associated with the risk of VTE.15-19 To identify high-risk 
individuals, de Haan et al created a genetic score based on 31 SNPs 
previously reported to increase VTE risk.20 In this score, the SNPs 
with highest odds ratios of VTE were added one-by-one to finally 
create a genetic risk score containing five SNPs: rs8176719 (non-O 
blood type) in ABO, rs6025 (factor V Leiden [FVL]) in F5, rs1799963 
(prothrombin G20210A) in F2, rs2066865 in the fibrinogen gamma 
gene (FGG), and rs2036914 in F11. This 5-SNP score performed 
similarly to the score of all 31 SNPs,20 and detected subjects at in-
creased risk of both incident and recurrent VTE.20-22
Genetic alterations such as Factor V Leiden,23,24 ABO rs505922 
and rs8176746,25 ABO rs8176719,26 and prothrombin G20210A27-30 
have all been found to be associated with VTE risk in cancer. 
Moreover, the combined effect of cancer and the factor 5 SNPs 
rs6025 and rs4524 increased VTE risk on a supra-additive scale, in-
dicating a biological interaction.24 As prothrombotic genotypes only 
need to be measured once, and are not influenced by disease pro-
gression, interventions, or complications, they are attractive candi-
date biomarkers of VTE risk in cancer patients.
The role of genetics in cancer-related VTE is not yet fully elucidated, 
and to the best of our knowledge, no previous study has investigated 
the impact of the 5-SNP score on VTE risk in cancer patients. Therefore, 
we aimed to investigate the impact of increasing number of risk alleles in 
the 5-SNP score on the risk of VTE in subjects with and without cancer 
using a case-cohort recruited from the general population.
2  | METHODS
2.1 | Study population
Study participants were derived from the fourth survey of the Tromsø 
Study, conducted in 1994-1995,31 and the second survey of the 
Nord-Trøndelag Health (HUNT) Study, conducted in 1995-1997.32 
The Tromsø Study (Tromsø 4) and the HUNT Study (HUNT2) are 
Norwegian population-based cohorts of the inhabitants of Tromsø 
municipality and Nord-Trøndelag County, respectively. A total of 
27 158 unique individuals aged ≥25 years participated in Tromsø 4, 
and 66 140 individuals aged ≥20 years participated in HUNT, yield-
ing attendance rates of 77% (Tromsø 4) and 71% (HUNT2). Detailed 
descriptions of the studies have been published elsewhere.31,32
Participants were followed from the date of inclusion until a 
verified first VTE diagnosis, migration, death, or end of follow-up 
(December 31, 2008 in HUNT2 and December 31, 2012 in Tromsø 
4). In Tromsø 4, all VTE events were identified by searching the 
hospital discharge diagnosis registry, the autopsy registry, and the 
radiology procedure registry at the University Hospital of North 
Norway (UNN), which is the sole provider of diagnostic radiology 
and treatment of VTE in the Tromsø area. Trained personnel re-
viewed the medical records for each potential VTE case, and incident 
VTE events were included when clinical signs and symptoms of PE or 
DVT were combined with radiologic confirmation and treatment was 
initiated (unless contraindications were specified). In HUNT2, VTE 
events were identified by searching the hospital discharge diagnosis 
registry and the radiology procedure registry at the two local hospi-
tals in the county (Levanger Hospital and Namsos Hospital) and by 
searching the discharge diagnosis registry of the tertiary-care center 
of the region, St. Olav's Hospital in Trondheim. Two physicians re-
viewed the medical records for each VTE event, and the validation 
criteria included symptomatic VTE events confirmed by radiologic 
procedures (ultrasound, venography, computed tomography [CT] 
scan, or perfusion-ventilation scan) which required treatment. The 
identification and adjudication process of VTEs in both studies have 
been previously described in detail.33,34 Participants with a history 
of VTE before inclusion in the parent cohorts were excluded.
We created a case-cohort by including all cases with a first life-
time VTE (n = 1493) and a randomly sampled subcohort (n = 13 072) 
derived from the parent cohorts (Figure 1). Participants not regis-
tered as inhabitants of Tromsø or Nord-Trøndelag at study inclusion 
(n = 3) and subjects with missing information on risk alleles (n = 170) 
or body mass index (n = 80) were excluded. Further, subjects with 
a cancer diagnosis prior to or less than 6 months after inclusion 
(n = 624) were excluded. Eventually, the case-cohort consisted of 
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13 688 participants, of whom 1362 were VTE cases. Due to the na-
ture of the case-cohort design, in which every person in the cohort, 
including the cases, has the same probability of being selected to the 
subcohort, 206 of the subjects randomly selected to the subcohort 
were also cases. All participants gave their informed written con-
sent to participate and The Regional Committee of Medical Health 
Research Ethics approved the study.
2.2 | Baseline measurements and genotyping
Baseline information was obtained by physical examination, blood 
sampling, and self-administrated questionnaires in each study. Body 
height and weight were measured with participants wearing light 
clothing and no shoes. Body mass index (BMI) was calculated by di-
viding the weight in kilograms (kg) by height in meters (m) squared 
(kg/m2). Information on history of cardiovascular disease (myocardial 
infarction, angina, or stroke), diabetes mellitus, and smoking status 
were obtained from the questionnaires.
DNA was isolated from blood, and the following five SNPs 
were genotyped: ABO rs8176719 (non-O blood type), F5 rs6025 
(Factor V Leiden), F2 rs1799963 (prothrombin G20210A), FGG 
rs2066865, and F11 rs2036914. In Tromsø 4, the Sequenom 
platform was used for genotyping rs8176719 (ABO), rs6025 
(F5), rs1799963 (F2), and rs2036914 (F11), while rs2066865 
(FGG) was genotyped with the TaqMan platform, as previously 
described.35 In HUNT2, genotyping was performed using the 
Illumina HumanCore Exome array.
F I G U R E  1   Study population. Participants were recruited from the fourth survey of the Tromsø study (1994-2012) and the second survey 
of the Nord-Trøndelag Health (1995-2008) study. VTE indicates venous thromboembolism; SNPs, single nucleotide polymorphisms
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Subjects were considered as carriers of prothrombotic geno-
types if one or two risk alleles were present. Hence, we did not dif-
ferentiate between hetero- and homozygous carriers. Because the 
minor allele at F11 rs2036914 is associated with reduced VTE risk,36 
the common allele was set as risk allele in our analysis. Zero risk al-
leles at ABO rs8176719 was defined as O blood type, whereas one 
or two risk alleles were classified as non-O blood type. The 5-SNP 
score conceived by de Haan et al was created by summing the num-
ber of risk alleles from the five sequenced SNPs.20
2.3 | Cancer assessment
Information on cancer diagnosis, primary cancer site (International 
Classification of Diseases, Revision 7 [ICD-7] codes 140-205), and 
stage during follow-up, was obtained by linkage to the Cancer 
Registry of Norway. The Cancer Registry of Norway is considered a 
complete and valid registry with reported 98.8% completeness and 
with 94% of the cases being histologically verified.37 Non-melanoma 
skin cancers (ICD-7 codes 191.0-191.9) were classified as non-can-
cer due to the pathophysiology and nature of these cancers.
As temporal proximity to cancer diagnosis is shown to be a strong 
predictor for VTE risk,1,24,38 a VTE event was classified as related to 
active cancer if it occurred within 6 months prior to a cancer diag-
nosis until 2 years following the cancer diagnosis date. Patients who 
were not diagnosed with VTE and still alive at the end of the active 
cancer period were censored at this time, as information regarding 
cancer progression and remission was not available and extending 
the active cancer period could result in dilution of the results by in-
cluding VTE events that were not related to cancer. Consequently, 
79 VTE events that occurred beyond the active cancer period were 
never counted in the analyses. Thus, the total number of VTE events 
in the analyses were 1283, of which 232 occurred in the active can-
cer period.
2.4 | Statistical analysis
Statistical analyses were carried out using STATA version 15.0 (Stata 
Corporation). Cancer was entered as a time-varying covariate and 
data were split in relation to cancer diagnosis date to distinguish be-
tween non-cancer and cancer-exposed periods. Individuals who de-
veloped cancer during follow-up contributed with exposure status 
as cancer-free until 6 months prior to their cancer diagnosis date, 
and from that point onward exposure status changed to active can-
cer. Two years after the cancer was diagnosed, the cancer patients 
who were still alive and had not experienced a VTE event were cen-
sored from the analyses. Thus, individuals who developed cancer 
contributed to both non-exposed and cancer-exposed person-years 
(PY) at risk during the study period.
Cox proportional hazard regression models were used to esti-
mate the hazard ratios (HRs) with 95% confidence intervals (CIs) for 
incident VTE according to the individual SNPs or categories of risk 
alleles (the 5-SNP score categories, ie, 0-1, 2-3, and ≥4 risk alleles) 
and by cancer status (cancer free and active cancer). In analyses 
stratified on cancer status, subjects with 0-1 risk alleles were used 
as reference category. All analyses were adjusted for age, sex, and 
BMI. The proportional hazard assumption was tested by the use of 
Schoenfeld residuals and was found not to be violated.
We also investigated the combined effect of cancer and risk al-
lele categories on VTE risk using cancer-free subjects with 0-1 risk 
alleles as reference category. The presence of a biological interac-
tion between cancer and presence of SNPs was calculated using 
the relative excess risk attributable to interaction (RERI), the attrib-
utable proportion due to interaction (AP), and the synergy index 
(SI) with corresponding 95% CIs.39,40 Briefly, the RERI can be inter-
preted as part of the total effect on outcome (eg, VTE) that is due 
to interaction (eg, between cancer and prothrombotic SNPs), the AP 
as the proportion of the combined effect that is attributable to in-
teraction between the two exposures. A RERI and an AP > 0, and a 
synergy index >1.0 suggest a positive interaction, ie, the combined 
effect of two exposures is larger than the sum of the two separate 
effects.39
3  | RESULTS
There were 1496 subjects diagnosed with cancer during a median 
follow-up of 12.3 years. The baseline characteristics of cancer-free 
subjects and cancer patients with and without VTE are presented in 
Table 1. In cancer-free subjects, participants who experienced a VTE 
were older, had more cardiovascular disease, and higher BMI than 
those without VTE. In cancer patients with VTE, there was a higher 
proportion of women and smokers and they were of younger age 
than cancer patients without VTE.
The proportions of non-cancer and cancer patients across in-
creasing number of risk alleles in the 5-SNP score are shown in 
Figure 2. The total number of risk alleles ranged from zero to seven 
in cancer-free subjects and from zero to six in cancer patients, with a 
median of two in both groups.
The risk estimates for VTE according to prothrombotic SNPs in 
subjects with and without cancer are presented in Table 2. In sub-
jects without cancer, all five SNPs were associated with an increased 
risk of VTE by the presence of one or more risk allele. The high-
est VTE risks were found for FVL (rs6025, HR 2.50, 95% CI 2.13-
2.95), prothrombin (rs1799963, HR 1.55, 95% CI 1.02-2.36), and 
ABO (rs8176719, HR 1.47, 95% CI 1.29-1.86). The greatest risk of a 
cancer-related VTE was seen in subjects with FVL (rs6025, HR 1.89, 
95% CI 1.29-2.77), prothrombin (rs1799963, HR 1.39, 95% CI 0.44-
4.37), and FGG (rs2066865, HR 1.34, 95% CI 1.03-1.74). Measures 
quantifying interaction on an additive scale (ie RERI, AP, and syn-
ergy index) suggested a positive interaction between cancer and the 
presence of three of the five prothrombotic SNPs; ABO (rs8176719), 
FVL (rs6025), and FGG (rs2066865; Table 3).
The risk of VTE increased across categories of increasing risk 
alleles in the 5-SNP score (0-1, 2-3, ≥4) in subjects with and without 
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cancer. In those without cancer, the HR for ≥4 versus 0-1 risk alleles 
was 2.17 (95% CI 1.79-2.62). In cancer patients, the correspond-
ing HR was 1.93 (95% CI 1.28-2.91). Similar results were found 
when analyzing DVT and PE separately (Table S1 in supporting 
information).
In subjects with 0-1 risk alleles, the risk of VTE was nine-fold 
higher in cancer patients than in those without cancer. Accordingly, 
there was a synergistic effect between the number of risk alleles and 
cancer on the relative risk of VTE. Subjects with cancer and ≥4 risk 
alleles had a 17-fold (HR 17.1, 95% CI 12.5-23.4) higher risk of VTE 
than cancer-free subjects with ≤1 risk allele. This combined effect 
was higher than expected on the basis of the individual effects of 
cancer and ≥4 risk alleles (RERI 6.72 95% CI 1.17-12.26). The AP re-
vealed that 39% of the total VTE events in participants with cancer 
and ≥4 risk alleles were attributable to the interaction between the 
two exposures (ie, cancer and ≥4 risk alleles).
4  | DISCUSSION
In this case-cohort study, we investigated the risk of cancer-related 
VTE by the presence of prothrombotic genotypes, both as individual 
SNPs and as categories of the 5-SNP score (0-1, 2-3, and ≥4 risk al-
leles).20 Moreover, we investigated whether the combination of 
cancer and prothrombotic genotypes had a biological interaction on 
VTE risk. For each prothrombotic genotype, the VTE risk increased 
in both cancer-free subjects and in cancer patients, and particularly 
for FVL, FGG, and ABO there was a more than additive effect in 
combination with cancer. When the 5-SNP score was applied, we 
found a dose-response relationship between the number of risk al-
leles and VTE risk in subjects with and without cancer. Likewise, the 
combined effect of cancer and the high-risk category of the genetic 
score (≥4 risk alleles) yielded a more than additive effect on VTE risk, 
with an HR of 17 compared with those without cancer in the low-
risk category (0-1 risk alleles). The AP revealed that 39% of the VTE 
events occurring among cancer patients with ≥ 4 risk alleles could be 
attributed to the interaction between the risk factors.
Our findings on the role of individual prothrombotic geno-
types and risk of cancer-related VTE are in line with the previ-
ously published studies. Factor V Leiden,23,24 ABO rs505922 and 
rs8176746,25 ABO rs8176719,26 prothrombin G20210A,27-30 and 
FGG rs206686541 have all been found to increase the risk of VTE 
in cancer patients. Moreover, SNPs in the F5 gene (FVL and rs4525) 
and FGG41 have been shown to exert a more than additive effect 
on VTE risk when combined with cancer. Accordingly, we found a 
positive RERI for the SNPs in ABO, FVL, and FGG, which indicated a 
biological interaction.
Even though the 5-SNP score has been shown to predict VTE risk 
in the general population,20 and in subjects with ischemic stroke,42 
the combined effect of the 5-SNP score and cancer has not been 
No cancer Cancer
Subcohort VTE Subcohort VTE
Participants, na  12 637 1051 1264 232
Age, y 50.2 ± 16.3 60.3 ± 15.1 62.0 ± 12.2 60.6 ± 13.4
Male sex 48.3 (5977) 47.8 (502) 53.2 (673) 44.4 (103)
BMI, kg/m2 26.2 ± 4.1 27.7 ± 4.5 26.8 ± 4.3 26.9 ± 4.2
Cardiovascular disease 7.7 (972) 14.1 (148) 12.3 (156) 12.1 (28)
Smoking 29.8 (3770) 25.0 (263) 32.2 (407) 34.9 (81)
rs8176719 (ABO)b  61.4 (7767) 69.9 (735) 60.6 (766) 68.1 (158)
rs6025 (F5)b  6.9 (873) 16.3 (171) 7.5 (95) 13.4 (31)
rs1799963 (F2)b  1.3(169) 2.1 (22) 1.3 (17) 1.29 (3)
rs2066865 (FGG)b  42.3 (5346) 45.9 (482) 40.8 (516) 47.8 (111)
rs2036914 (F11)b  78.2 (9879) 82.5 (867) 78.6 (994) 81.0 (188)
Note: Values are in % (n) or mean ± standard deviation.
Abbreviations: BMI, body mass index; VTE, venous thromboembolism.
aParticipants with cancer contributed to observation periods both in the no cancer and cancer 
group. 
bPercentage of participants with ≥1 risk allele. 
TA B L E  1   Baseline characteristics of 
the study population with and without 
cancer and VTE
F I G U R E  2   Distribution (%) of individuals across number (#) of 
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studied previously. In cancer patients, those with ≥4 risk alleles had 
an almost two-fold higher VTE-risk than those with 0-1 risk alleles, 
and the combination of cancer and ≥4 risk alleles yielded a 17-fold 
increased risk. As 39% of the VTEs occurring among those with 
cancer and the high-risk category of the genetic risk score could be 
attributed to the biological interaction, our findings suggest that ge-
netics could be a useful tool for identifying cancer patients at high 
risk of VTE. However, the predictive performance of the 5-SNP 
score remains to be determined.
Risk factors for VTE in cancer can be broadly categorized into 
patient-related, cancer-related, and treatment-related factors. 
Prothrombotic genotypes are examples of patient-related factors 
that determine the intrinsic thrombosis potential of a patient and 
are not influenced by the disease or its progression. The finding 
that cancer and prothrombotic genotypes have a more than addi-
tive effect on VTE risk is especially interesting, as it could indicate 
that prothrombotic SNPs act through pathophysiological pathways 
that further increases the procoagulant state of malignancy. The 
five SNPs are all related to functions of the coagulation system and 
enhance its performance. Malignant tumors release cell-free DNA, 
procoagulant factors such as tissue factor, and growth factors that 
promote the release of neutrophil extracellular traps (NETs) from 
neutrophils.43 These are main triggers of the intrinsic and extrin-
sic pathways of the coagulation system that in combination with 
n Events HR (95% CI)a  HR (95% CI)a 
Cancer rs8176719 (ABO)b 
− − 5210 316 Ref. Ref.
− + 8502 735 1.47 (1.29-1.68) 1.48 (1.29-1.69)
+ − 562 74 Ref. 8.68 (6.73-11.20)
+ + 934 158 1.31 (0.99-1.73) 11.07 (9.12-13.44)
Cancer rs6025 (F5)b 
− − 12 644 880 Ref. Ref.
− + 1044 171 2.50 (2.13-2.95) 2.50 (2.12-2.95)
+ − 1370 201 Ref. 8.16 (6.98-9.54)
+ + 126 31 1.89 (1.29-2.77) 15.95 (11.12-22.87)
Cancer rs1799963 (F2)b 
− − 13 497 1029 Ref. Ref.
− + 191 22 1.55 (1.02-2.36) 1.55 (1.02-2.37)
+ − 1476 229 Ref. 7.93 (6.85-9.18)
+ + 20 3 1.39 (0.44-4.37) 9.05 (2.91-28.17)
Cancer rs2066865 (FGG)b 
− − 7860 569 Ref. Ref.
− + 5828 482 1.14 (1.01-1.28) 1.14 (1.01-1.28)
+ − 869 121 Ref. 7.36 (6.03-8.98)
+ + 627 111 1.34 (1.03-1.74) 9.78 (7.96-12.01)
Cancer rs2036914 (F11)b 
− − 2942 184 Ref. Ref.
− + 10 746 867 1.27 (1.08-1.49) 1.27 (1.08-1.49)
+ − 314 44 Ref. 9.21 (6.62-12.81)
+ + 1182 188 1.11 (0.79-1.54) 9.63 (7.84-11.83)
Cancer 5-SNP scorec 
− 0-1 3106 170 Ref. Ref.
− 2-3 8111 589 1.33 (1.12-1.57) 1.33 (1.12-1.57)
− ≥4 2471 292 2.17 (1.79-2.62) 2.15 (1.78-2.60)
+ 0-1 322 41 Ref. 9.16 (6.51-12.90)
+ 2-3 931 139 1.18 (0.83-1.68) 10.3 (8.21-12.9)
+ ≥4 243 52 1.93 (1.28-2.91) 17.1 (12.5-23.4)
aAdjusted for age, sex, and body mass index. 
bPositive indicating subjects with one or two risk alleles. 
cNumber of risk alleles. 
TA B L E  2   Hazard ratios (HR) with 
95% confidence intervals (CI) for venous 
thromboembolism (VTE) by categories of 
prothrombotic genotypes and cancer
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prothrombotic genotypes will facilitate downstream coagulation 
activation with subsequent increased risk of thrombus formation. 
Moreover, acquired resistance to activated protein C is common in 
cancer patients, and may contribute to further increase the risk in 
patients with FVL.44
For decisions on use of thromboprophylaxis in cancer pa-
tients, the risk of VTE needs to be evaluated and weighted 
against the risk of bleeding. Several risk prediction models for 
VTE risk have been proposed, such as the Khorana score,45 the 
Vienna CATS score,46 the PROTECHT score,47 and the CONKO 
score.48 However, these risk scores focus mainly on clinical risk 
factors, and currently, they are not recommended in international 
guidelines due to unsatisfying performances in validation studies. 
The TiC-Onco score is the only score that includes genetics,49 
and in this score, eight prothrombotic SNPs were investigated to-
gether with clinical variables. The final TiC-Onco score included 
four SNPs (FVL rs6025, F5 rs4524, F13 rs5985, and SERPINA10 
rs2232698). Of note, the TiC-Onco score performed better than 
the Khorana score in the derivation study,49 but the performance 
of these two models has not been compared in a validation study. 
Nevertheless, the TiC-Onco results supports that prothrombotic 
genotypes may be promising candidates for risk prediction of VTE 
in cancer patients.
Major strengths of our study include the large number of 
genotyped subjects followed for a long period of time, the high 
attendance rate in the two cohorts, and the thorough outcome as-
sessment. Further, confounding by ethnicity is limited as the study 
cohorts represent a general Caucasian population. Some limita-
tions of our study need to be addressed. The number of cases was 
low in some subgroups, particularly for the rare genetic variants, 
which resulted in limited statistical power. The subgroup results 
must therefore be interpreted with caution. The effect of genetic 
variants may vary in different types of cancer, but unfortunately, 
we did not have power to stratify our analyses on cancer types. 
Unfortunately, information on cancer treatment modalities was 
not available, which could have provided additional insight to the 
relationship between genes and treatment-related risk factors for 
cancer.
In conclusion, cancer and a high number of prothrombotic gen-
otypes displayed a supra-additive effect on the risk of VTE, indicat-
ing a biological interaction between the risk factors. Our findings 
suggest that the 5-SNP score may be useful for identifying cancer 
patients at increased risk of VTE.
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